The stock of Blueprint Medicines Corp (BPMC) has gone up by 0.30% for the week, with a 0.52% rise in the past month and a 57.39% rise in the past quarter. The volatility ratio for the week is 0.20%, and the volatility levels for the past 30 days are 0.24% for BPMC. The simple moving average for the last 20 days is 0.28% for BPMC stock, with a simple moving average of 31.12% for the last 200 days.
Is It Worth Investing in Blueprint Medicines Corp (NASDAQ: BPMC) Right Now?
The stock has a 36-month beta value of 0.94. Opinions on the stock are mixed, with 9 analysts rating it as a “buy,” 6 as “overweight,” 17 as “hold,” and 1 as “sell.”
The public float for BPMC is 62.27M, and at present, short sellers hold a 5.02% of that float. On July 08, 2025, the average trading volume of BPMC was 3.00M shares.
BPMC) stock’s latest price update
Blueprint Medicines Corp (NASDAQ: BPMC) has seen a rise in its stock price by 0.12% in relation to its previous close of $128.4. However, the company has experienced a 0.30% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-20 that NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and also will receive one non-tradeable contingent value right (CVR) entitling the holder to receive t.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with Wedbush repeating the rating for BPMC by listing it as a “Neutral.” The predicted price for BPMC in the upcoming period, according to Wedbush is $129 based on the research report published on June 02, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $100. The rating they have provided for BPMC stocks is “Equal-Weight” according to the report published on March 20th, 2025.
BPMC Trading at 13.49% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.03% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Carter Percy H., who sale 2,659 shares at the price of $127.88 back on Jun 03 ’25. After this action, Carter Percy H. now owns 54,206 shares of Blueprint Medicines Corp, valued at $340,033 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, sale 5,000 shares at $101.14 during a trade that took place back on May 27 ’25, which means that Albers Jeffrey W. is holding 146,630 shares at $505,692 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.31 for the present operating margin
- 0.96 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.28. The total capital return value is set at -0.18. Equity return is now at value -47.71, with -13.94 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -1.19. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is -3.82.
Currently, EBITDA for the company is 19.23 million with net debt to EBITDA at -0.0. When we switch over and look at the enterprise to sales, we see a ratio of 14.79. The receivables turnover for the company is 7.04for trailing twelve months and the total asset turnover is 0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.80.
Conclusion
To sum up, Blueprint Medicines Corp (BPMC) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
